SDGR Stock Overview
Develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Schrödinger, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.17 |
| 52 Week High | US$38.00 |
| 52 Week Low | US$16.67 |
| Beta | 1.5 |
| 11 Month Change | 6.98% |
| 3 Month Change | -1.64% |
| 1 Year Change | -37.50% |
| 33 Year Change | -51.23% |
| 5 Year Change | n/a |
| Change since IPO | -33.07% |
Recent News & Updates
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher
Nov 13
Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty
Oct 17Recent updates
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher
Nov 13Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty
Oct 17Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues
Sep 27Schrodinger: More Drug Discovery Validation
Aug 06Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation
Aug 05We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right
Jun 12Schrödinger: More Pharmaceutical Than Software
May 07Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar
May 02Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially
Mar 01Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
Mar 01Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Feb 28The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%
Feb 01Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable
Dec 18Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Sep 28Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?
Jul 01Schrödinger: Q2 Earnings Supports Growth Narrative
Aug 26Schrödinger appoints Dr. Geoffrey Porges as finance chief
Aug 18Sizing Up Schrodinger
Jun 06Schrödinger: Holding The Keys To Discovery
Mar 26Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too
Mar 15Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical
Jan 06Shareholder Returns
| SDGR | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -13.2% | -8.3% | -1.0% |
| 1Y | -37.5% | 5.7% | 30.3% |
Return vs Industry: SDGR underperformed the US Healthcare Services industry which returned 5.7% over the past year.
Return vs Market: SDGR underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SDGR volatility | |
|---|---|
| SDGR Average Weekly Movement | 7.6% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SDGR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SDGR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 867 | Ramy Farid | www.schrodinger.com |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Schrödinger, Inc. Fundamentals Summary
| SDGR fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$177.58m |
| Revenue (TTM) | US$193.35m |
7.2x
P/S Ratio-7.9x
P/E RatioIs SDGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SDGR income statement (TTM) | |
|---|---|
| Revenue | US$193.35m |
| Cost of Revenue | US$67.85m |
| Gross Profit | US$125.50m |
| Other Expenses | US$303.08m |
| Earnings | -US$177.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 64.91% |
| Net Profit Margin | -91.84% |
| Debt/Equity Ratio | 0% |
How did SDGR perform over the long term?
See historical performance and comparison